Aarti Drugs Limited — Updates, 24-10-2024: Press Release

Aarti Drugs Limited reported a decline in financial performance for Q2 and H1 FY25, with revenues at Rs. 599.8 crores and Rs. 1,156.3 crores, down 7% and 11% YoY, respectively. EBITDA and PAT also decreased by 11% and 12% YoY. The company completed a buyback of 6,65,000 shares at Rs. 900 each. Notably, a greenfield project for specialty chemicals is set to commence, aiming to enhance capacity utilization. Total capex for the year is projected at Rs. 200 crores.